Skip to main content
. 2022 Oct 5;11(19):3131. doi: 10.3390/cells11193131

Figure 2.

Figure 2

Inhibiting STAT3 signaling at multiple levels for OSCC treatment. Currently, the majority of STAT3 inhibitors have been developed to target different sites in the STAT3 pathway: (1) targeting the upstream regulators of STAT3 [110,111], (2) binding to the SH2 domain of STAT3 and inhibiting its activation [112], (3) inhibiting STAT3 phosphorylation [113], (4) nuclear-targeted siRNA delivery for STAT3 gene silencing [114,115], (5) regulating downstream targets of STAT3 [116,117,118]. Reproduced/adopted in modified form from [56].